vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $50.4M, roughly 1.1× Armour Residential REIT, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -83.0%, a 503.2% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 36.9%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 48.5%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ARR vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $57.3M |
| Net Profit | $211.7M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 420.2% | -83.0% |
| Revenue YoY | 297.9% | 36.9% |
| Net Profit YoY | 555.9% | -9.6% |
| EPS (diluted) | $2.43 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $57.3M | ||
| Q3 25 | $38.5M | $51.3M | ||
| Q2 25 | $33.1M | $48.5M | ||
| Q1 25 | $36.3M | $32.7M | ||
| Q4 24 | $12.7M | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | $7.0M | $29.1M | ||
| Q1 24 | — | $26.0M |
| Q4 25 | $211.7M | $-47.5M | ||
| Q3 25 | $159.3M | $-52.9M | ||
| Q2 25 | $-75.6M | $-46.6M | ||
| Q1 25 | $27.3M | $-49.5M | ||
| Q4 24 | $-46.4M | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | $-48.4M | $-32.3M | ||
| Q1 24 | — | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | 420.2% | -83.0% | ||
| Q3 25 | 413.5% | -103.1% | ||
| Q2 25 | -228.4% | -96.1% | ||
| Q1 25 | 75.2% | -151.4% | ||
| Q4 24 | -366.8% | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | -693.8% | -110.9% | ||
| Q1 24 | — | -544.4% |
| Q4 25 | $2.43 | $-0.73 | ||
| Q3 25 | $1.49 | $-0.82 | ||
| Q2 25 | $-0.94 | $-0.75 | ||
| Q1 25 | $0.32 | $-0.81 | ||
| Q4 24 | $-0.91 | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | $-1.05 | $-0.55 | ||
| Q1 24 | — | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $139.1M |
| Total Assets | $21.0B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $388.9M | ||
| Q3 25 | $44.2M | $416.1M | ||
| Q2 25 | $141.2M | $291.0M | ||
| Q1 25 | $49.1M | $314.5M | ||
| Q4 24 | $68.0M | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | $126.6M | $319.1M | ||
| Q1 24 | — | $201.2M |
| Q4 25 | $2.3B | $139.1M | ||
| Q3 25 | $2.1B | $148.8M | ||
| Q2 25 | $1.7B | $-11.9M | ||
| Q1 25 | $1.7B | $18.9M | ||
| Q4 24 | $1.4B | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | $1.2B | $39.3M | ||
| Q1 24 | — | $61.6M |
| Q4 25 | $21.0B | $480.2M | ||
| Q3 25 | $19.4B | $506.9M | ||
| Q2 25 | $16.2B | $372.7M | ||
| Q1 25 | $15.5B | $386.7M | ||
| Q4 24 | $13.5B | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | $10.1B | $381.8M | ||
| Q1 24 | — | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-25.4M | ||
| Q3 25 | $-37.8M | $-26.6M | ||
| Q2 25 | $25.0M | $-23.3M | ||
| Q1 25 | $101.5M | $-40.4M | ||
| Q4 24 | $261.5M | $-18.8M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | $27.1M | $-29.1M | ||
| Q1 24 | — | $-40.7M |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
